Inclusion Criteria:

          -  For the lead in phase: Patients >= 18 years of age with a diagnosis of relapsed and/or
             refractory AML will be eligible. Patients who have had prior treatment with venetoclax
             will be allowed to participate in the lead in phase and cohort A

          -  For the dose expansion cohort A (relapsed/refractory [R/R] AML): Patients >= 18 years
             of age with a diagnosis of relapsed and/or refractory AML will be eligible

          -  For the dose expansion cohort B (de novo AML): Patients >= 18 years to 69 years of
             age; patients in this cohort must have received no prior therapy for AML

          -  Prior therapy with hydroxyurea, hematopoietic growth factors, or tretinoin (ATRA) (for
             emergency use for stabilization) is allowed with no washout. A cumulative dose of
             ara-C of up to 3 g for emergency stabilization in patients with rapidly proliferating
             disease is also allowed provided it was administered > 48 hrs prior to enrollment

          -  Bilirubin =< 2 mg/dL

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper
             limit of normal (ULN) or < 5 x ULN if related to leukemic involvement

          -  Creatinine =< 1.5 x ULN

          -  Known cardiac ejection fraction of > or = 45% within the past 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  A negative urine or serum pregnancy test is required within 1 week for all women of
             childbearing potential prior to enrolling on this trial. A woman of childbearing
             potential is defined as a woman who has not been naturally postmenopausal for at least
             12 consecutive months, or who had no previous surgical sterilization

          -  Patient must have the ability to understand the requirements of the study and signed
             informed consent. A signed informed consent by the patient or his legally authorized
             representative is required prior to their enrollment on the protocol

        Exclusion Criteria:

          -  Pregnant women are excluded from this study because the agents used in this study have
             the potential for teratogenic or abortifacient effects. Because there is a potential
             risk for adverse events in nursing infants secondary to treatment of the mother with
             the chemotherapy agents, breastfeeding should also be avoided

          -  Uncontrolled intercurrent illness including, but not limited to active uncontrolled
             infection, symptomatic congestive heart failure (New York Heart Association [NYHA]
             class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia,
             or psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Patient with documented hypersensitivity to any of the components of the chemotherapy
             program

          -  Patients with acute promyelocytic leukemia (M3) or core-binding factor AML

          -  Patients with active central nervous system (CNS) leukemia are excluded since the
             antileukemia activity of the treatment components against CNS leukemia are not known

          -  Men and women of childbearing potential who do not practice contraception. Women of
             childbearing potential and men must agree to use contraception prior to study entry
             and for the duration of study participation

          -  Prior treatment with CPX-351 or venetoclax. Patients with prior treatment with
             venetoclax will be allowed in patients with relapsed/refractory (R/R) disease
             including those in the lead-in phase as well as those in cohort A